Cargando…
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
PBI-4050 is a novel orally active small-molecule compound with demonstrated anti-fibrotic activity in several models of fibrosis, including lung fibrosis. We present results from our first clinical study of PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF). This 12-week open-label study...
Autores principales: | Khalil, Nasreen, Manganas, Helene, Ryerson, Christopher J., Shapera, Shane, Cantin, Andre M., Hernandez, Paul, Turcotte, Eric E., Parker, Joseph M., Moran, John E., Albert, Gary R., Sawtell, Renata, Hagerimana, Aline, Laurin, Pierre, Gagnon, Lyne, Cesari, Frank, Kolb, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422836/ https://www.ncbi.nlm.nih.gov/pubmed/30578394 http://dx.doi.org/10.1183/13993003.00663-2018 |
Ejemplares similares
-
Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial
por: Baig, Shanat, et al.
Publicado: (2018) -
The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry
por: Ryerson, Christopher J., et al.
Publicado: (2016) -
A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020) -
Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort
por: Marcoux, Veronica, et al.
Publicado: (2023) -
Acute mountain sickness and sleep disturbances differentially influence cognition and mood during rapid ascent to 3000 and 4050 m
por: Figueiredo, Peter S., et al.
Publicado: (2022)